sEphB4-HSA

Drug Profile

sEphB4-HSA

Alternative Names: EphB4-HSA; EphB4-Human Serum Albumin; Human Serum Albumin-EphB4 conjugate; Vas 01

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator VasGene Therapeutics
  • Developer National Cancer Institute (USA); University of Southern California; VasGene Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action EphB4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Kaposi's sarcoma; Solid tumours

Most Recent Events

  • 08 Feb 2017 The University of Southern California and the National Cancer Institute plans a clinical study for Non-small cell lung cancer and Head and neck cancer (Combination therapy, Second-line therapy, Late-stage disease, Metastatic disease) in USA (NCT03049618)
  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 09 Jun 2016 Vasgene Therapeutics and AIDS Malignancy Consortium suspend patient recruitment of a phase II trial in Kaposi's sarcoma due to drug supply issues in USA (IV) before June 2016 (NCT02799485)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top